In this free webinar, learn the need for reliable estimation of the inhibitory effect of oncological drugs using lower sample size. Attendees will learn about various models for the estimation of tumour growth rate ('g'), including exponential models. The featured speakers will discuss the value and pitfalls of tumour characterisation using radiomics. Attendees will learn about the advantages of volumetric assessment of tumour size when compared to conventional line measurements. The speakers will also discuss how the power of AI can be harnessed to facilitate better extraction of tumour volume.
TORONTO, Sept. 28, 2023 /PRNewswire-PRWeb/ -- The use of medical imaging biomarkers to better understand the efficacy of cancer drugs, aided by the power of AI.
Oncology clinical trials would benefit greatly from new biomarkers that could help to better understand the efficacy of drug treatments. Growth rate ('g') of tumour derived by appropriate tumour growth rate (TGR) modelling, as well as quantitative estimation of tumour heterogeneity through radiomics are two processes that offer such oncological imaging biomarkers.
Response evaluation criteria in solid tumours (RECIST) 1.1 and other similar criteria for tumour burden assessments have been used conventionally for the investigation of the tumour-inhibitory effect of cancer drugs. A large sample size is commonly required for both a reliable estimation of overall survival from such criteria, and to differentiate from the control arm. However, the 'g' value obtained through effective TGR modelling may provide a more efficient alternative to understanding drug efficacy using a lower sample size.
Radiomics is the extraction of quantitative metrics from medical images that characterise tumour heterogeneity. Radiomic features (both cross-sectional and longitudinal changes) have been associated with tumour aggressiveness and may predict clinical and clinical trial endpoints like survival.
In this webinar, we will discuss the basics of TGR modelling from oncological imaging data, as well as radiomics. We will also look at how AI can be harnessed for a more automated tumour volume detection, and how this can aid with simultaneous assessment of both 'g' as well as radiomics features.
Join experts from ICON, Paul McCracken, PhD, Vice President, Global Head of Medical Imaging; Ramkumar Krishnamurthy, PhD, Medical Imaging Scientist II; and Meena Makary, PhD, Medical Imaging Scientist II, for the live webinar on Thursday, October 12, 2023, at 10am EDT (4pm CEST/EU-Central).
For more information, or to register for this event, visit Advances in oncological imaging: Tumour growth rate modelling and radiomics.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], www.xtalks.com
SOURCE Xtalks
Share this article